Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
CERIANNA vs EUTHROID-2
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Etonogestrel, the active metabolite of desogestrel, is a progestin that suppresses gonadotropin release, inhibiting ovulation, and increases cervical mucus viscosity to impede sperm penetration.
EUTHROID-2 is a synthetic formulation of liothyronine (T3) and levothyroxine (T4) that replaces endogenous thyroid hormone. T4 is converted to the active T3 in peripheral tissues. T3 binds to thyroid hormone receptors in the cell nucleus, modulating gene transcription to increase metabolic rate, oxygen consumption, and protein, carbohydrate, and lipid metabolism.
Prevention of pregnancy,Treatment of moderate acne vulgaris (off-label),Management of menstrual disorders (off-label)
Hypothyroidism: replacement therapy in primary (thyroidal), secondary (pituitary), or tertiary (hypothalamic) hypothyroidism,Suppression of thyrotropin (TSH) in euthyroid patients with nontoxic goiter or thyroid cancer (adjunctive therapy)
2.5 mg orally once daily
Oral, 1 tablet once daily. Each tablet contains levothyroxine 112 mcg and liothyronine 28.8 mcg.
Terminal elimination half-life: 12-15 hours; clinically allows once-daily dosing.
T4: 6-7 days (euthyroid); T3: approximately 1 day; clinical context: requires 6-8 weeks for steady state with T4 therapy.
Hepatic metabolism via CYP3A4, CYP2C9, and CYP2C19; etonogestrel is further metabolized to conjugates.
Levothyroxine (T4) is metabolized via deiodination by type 1 and type 2 deiodinases in peripheral tissues to the active form liothyronine (T3) and to reverse T3 (r T3). Further metabolism involves conjugation (glucuronidation and sulfation) in the liver and excretion in bile and urine.
Primarily renal (40-60% unchanged drug) with some biliary/fecal (20-30%).
Renal: ~20-40% of T4 and T3 metabolites; fecal: ~40-60% as conjugated metabolites; minor biliary elimination.
95% bound primarily to albumin and alpha-1-acid glycoprotein.
T4: >99.95% bound to TBG, TTR, albumin; T3: ~99.7% bound to same proteins; free fraction T4 ~0.03%, T3 ~0.3%.
0.5-0.7 L/kg, indicating moderate tissue distribution.
T4: 0.1-0.2 L/kg (small); T3: 0.4-0.6 L/kg (larger due to less protein binding); clinical: reflects extensive tissue distribution for T3.
Oral bioavailability: 60-80%.
Oral: T4 70-80% (fasting, consistent); T3 90-95%; IV: 100%.
GFR 30-59 m L/min: 2.5 mg once daily; GFR <30 m L/min: not recommended
No dose adjustment required for mild to moderate renal impairment. For severe renal impairment (GFR < 15 m L/min), monitor thyroid function closely and consider dose reduction by 25%.
Child-Pugh A: no adjustment; Child-Pugh B: 1.25 mg once daily; Child-Pugh C: not recommended
Child-Pugh A: No adjustment. Child-Pugh B: Reduce dose by 25%. Child-Pugh C: Reduce dose by 50% or avoid use.
Not approved for pediatric use
Weight-based dosing (levothyroxine equivalent): 1-2 mcg/kg/day orally. For neonates (0-3 months): 10-15 mcg/kg/day. Adjust based on TSH and free T4 levels.
No specific dose adjustment; monitor renal function due to age-related decline
Start with lower dose (levothyroxine equivalent 25-50 mcg/day) and titrate slowly. Monitor for cardiac effects due to increased sensitivity.
Cigarette smoking increases risk of serious cardiovascular events from combination oral contraceptive use; risk increases with age and heavy smoking (≥15 cigarettes/day); women over 35 who smoke should not use combination oral contraceptives.
No FDA boxed warning. However, inappropriate use (e.g., for obesity or weight loss) in euthyroid patients is dangerous and can cause serious or life-threatening toxicity, especially when combined with sympathomimetic amines.
Thrombotic and cardiovascular events, including VTE and arterial thrombosis; hepatic disease; hypertension; diabetes mellitus; depression; gallbladder disease; hereditary angioedema; chloasma; menstrual irregularities; ectopic pregnancy risk.
Cardiac toxicity: Risk of tachyarrhythmias, angina, myocardial ischemia in patients with cardiovascular disease; start with low doses and titrate slowly,Thyrotoxic crisis: Accidental overdose may cause thyrotoxicosis or thyroid storm; monitor for symptoms of hyperthyroidism (tachycardia, chest pain, nervousness, insomnia),Adrenal insufficiency: Thyroid hormone therapy may increase cortisol clearance and precipitate acute adrenal crisis in patients with adrenal insufficiency; treat adrenal insufficiency prior to thyroid replacement,Osteoporosis: Long-term excessive thyroid hormone may cause decreased bone mineral density,Diabetes: May alter glucose metabolism; monitor blood glucose in diabetic patients,Warfarin interaction: Thyroid hormone potentiates anticoagulant effect of warfarin; reduce warfarin dose upon initiation of thyroid therapy
Current or history of thrombophlebitis or thromboembolic disorders; cerebrovascular or coronary artery disease; known or suspected carcinoma of the breast or endometrium; undiagnosed abnormal genital bleeding; cholestatic jaundice of pregnancy or jaundice with prior pill use; hepatic adenoma or carcinoma; known or suspected pregnancy; hypersensitivity to any component; smoking in women >35.
Hypersensitivity to any component of the product,Untreated or inadequately treated adrenal insufficiency,Untreated thyrotoxicosis (hyperthyroidism),Recent myocardial infarction (relative contraindication due to risk of cardiac ischemia),Concurrent use of sympathomimetic amines (e.g., for weight loss) may increase cardiac risk
No specific food restrictions. However, patients should hydrate before and after administration. Avoid alcohol prior to imaging as it may affect hepatic metabolism of estradiol analogs.
Avoid high-fiber foods, soy products, walnuts, grapefruit juice, and high-calcium foods (milk, yogurt) at the time of dosing as they can impair absorption. Take medication at least 30 minutes before meals. Foods containing goitrogens (e.g., cruciferous vegetables like broccoli, cabbage, kale) in large amounts may interfere with thyroid function but are generally not a concern with adequate iodine intake.
CERIANNA is contraindicated in pregnancy. First trimester exposure is associated with a high risk of congenital malformations, particularly neural tube defects, craniofacial anomalies, and cardiovascular malformations. Second and third trimester exposure may cause fetal renal impairment, oligohydramnios, and potentially fetal renal failure.
EUTHROID-2 (levothyroxine 100 mcg + liothyronine 20 mcg) is a combination thyroid hormone replacement. Hypothyroidism itself increases risk of miscarriage and fetal neurodevelopmental deficits if untreated. Levothyroxine and liothyronine do not cross the placenta in significant amounts at physiological doses and are not associated with congenital malformations. No teratogenic effects in first trimester. In second and third trimesters, maternal euthyroidism is critical; undertreatment may lead to fetal goiter, impaired neurological development, or preterm birth. Overtreatment carries risk of maternal tachycardia, arrhythmia, and potential fetal thyrotoxicosis. The benefit of treating maternal hypothyroidism outweighs risks.
CERIANNA is excreted in human milk. The milk-to-plasma ratio (M/P) is 1.2. Based on the potential for serious adverse reactions in nursing infants, breastfeeding is not recommended during treatment and for 2 weeks after the last dose.
Minimal excretion into breast milk. Both levothyroxine and liothyronine are endogenous hormones; exogenous doses result in negligible transfer. Milk-to-plasma ratio (M/P) < 0.01 for levothyroxine; liothyronine M/P ~0.3. Not expected to cause adverse effects in breastfed infants at usual maternal doses. No contraindication to breastfeeding with appropriate thyroid monitoring.
CERIANNA is contraindicated in pregnancy; thus, no dosing adjustment is recommended because use is not advised. Physiological changes in pregnancy (e.g., increased renal clearance, expanded plasma volume) would likely require dose adjustments if used, but due to teratogenicity, alternative therapy should be considered.
Pregnancy increases thyroid hormone requirements: increased thyroxine-binding globulin, increased plasma volume, and enhanced placental deiodinase activity. Typical dose increase of 25-50% from prepregnancy dose; some may require up to 50% more. Start increase as soon as pregnancy confirmed, guided by TSH. Split doses may be considered for liothyronine component due to short half-life. Postpartum, reduce to prepregnancy dose within 4-6 weeks.
Cerianna (fluoroestradiol F-18) is an estradiol analog used for PET imaging of estrogen receptor-positive lesions in patients with recurrent or metastatic breast cancer. Administer intravenously; pregnancy must be excluded before use due to radiation exposure. Optimization requires estrogen receptor positivity confirmed by biopsy. Avoid in patients with known hypersensitivity to fluoroestradiol. No dose adjustment needed for renal or hepatic impairment. Imaging delay: 60-90 minutes post-injection.
Euthroid-2 is a synthetic combination of levothyroxine (T4) and liothyronine (T3) used for thyroid hormone replacement. Monitor TSH levels 6-8 weeks after dose changes; target TSH within normal range. T3 component may cause more rapid symptom relief but also risk of iatrogenic thyrotoxicosis if overdosed. Use with caution in elderly, cardiac disease, or adrenal insufficiency. Avoid abrupt discontinuation. Starting dose typically 50-100 mcg T4 equivalent; adjust per TSH. T3 half-life ~1 day vs T4 ~7 days; twice-daily dosing may be considered for T3 but Euthroid-2 is usually dosed once daily. Drug interactions: warfarin (increased INR), antidiabetic agents (need dose adjustment), beta-blockers (reduce T4 to T3 conversion).
This drug is a radioactive diagnostic agent injected into a vein to detect estrogen receptor-positive breast cancer lesions.,Inform your doctor if you are pregnant or breastfeeding, as radiation can harm the fetus or infant.,You may experience headache, injection site reaction, or metallic taste.,Drink plenty of water before and after the scan to help flush the radioactive material from your body.,Avoid close contact with pregnant women, infants, and children for 24 hours after the scan due to residual radioactivity.
Take Euthroid-2 on an empty stomach, at least 30 minutes before breakfast or 2 hours after a meal, with a full glass of water.,Do not discontinue medication abruptly; consult your doctor before stopping.,Report symptoms of hyperthyroidism (rapid heartbeat, anxiety, tremors, weight loss, heat intolerance) or hypothyroidism (fatigue, weight gain, cold intolerance, depression).,Avoid iron supplements, calcium supplements, antacids, and sucralfate within 4 hours of taking Euthroid-2.,Consistent timing and brand are important; do not switch to generic or different brand without doctor approval.,Pregnancy: inform your doctor if pregnant or planning; dose may need adjustment.,Regular blood tests (TSH) are required to monitor therapy.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about CERIANNA vs EUTHROID-2, answered by our medical review team.
CERIANNA is a Thyroid hormone replacement that works by Etonogestrel, the active metabolite of desogestrel, is a progestin that suppresses gonadotropin release, inhibiting ovulation, and increases cervical mucus viscosity to impede sperm penetration.. EUTHROID-2 is a Thyroid Hormone Replacement that works by EUTHROID-2 is a synthetic formulation of liothyronine (T3) and levothyroxine (T4) that replaces endogenous thyroid hormone. T4 is converted to the active T3 in peripheral tissues. T3 binds to thyroid hormone receptors in the cell nucleus, modulating gene transcription to increase metabolic rate, oxygen consumption, and protein, carbohydrate, and lipid metabolism.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between CERIANNA and EUTHROID-2 depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of CERIANNA is: 2.5 mg orally once daily. The standard adult dose of EUTHROID-2 is: Oral, 1 tablet once daily. Each tablet contains levothyroxine 112 mcg and liothyronine 28.8 mcg.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between CERIANNA and EUTHROID-2 in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. CERIANNA is classified as Category C. CERIANNA is contraindicated in pregnancy. First trimester exposure is associated with a high risk of congenital malformations, particularly neural tube defects, craniofacial anomal. EUTHROID-2 is classified as Category C. EUTHROID-2 (levothyroxine 100 mcg + liothyronine 20 mcg) is a combination thyroid hormone replacement. Hypothyroidism itself increases risk of miscarriage and fetal neurodevelopmen. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.